Back to results
US 9,040,532 B2Granted
Alpha adrenergic receptor modulators
AssigneeAllergan, Inc.
InventorsKen Chow, Liming Wang, Wenkui K. Fang, Evelyn G. Corpuz, Santosh C. Sinha, Daniel W. Gil, Mohammad I. Dibas, John E. Donello
Life of this patent
Estimating the term…
Abstract
Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.
Claims14
A compound having formula I, its enantiomers, diastereoisomers, tautomers or a pharmaceutically acceptable salt thereof
- wherein:
- n is 0 or 1;
- A is an aromatic or non-aromatic ring;
- X is N, N—R1, CH—R1, C—R1;
- R1 is H, C1-6 alkyl or halogen;
- R2 is N, N—R3, CH—R3, C—R3, O or S;
- R3 is H, halogen, or C1-6 alkyl;
- R4 is halogen, H, C1-6 alkyl or part of a ring as a S, O, N or as a C;
- R5 is a S, N or is a C and is always part of a ring;
- R6 is H, C1-6 alkyl, halogen or is part of a ring as a S, O, N or as a C;
- R4 and R5 can form a 5 or 6 membered carbo- or heterocyclic ring, aromatic or non-aromatic, optionally substituted with 1 to 2 C1-6 alkyl or with 1 to 2 halogen and is directly attached to the rest of the molecule;
- or
- R5 and R6 can form a 5 or 6 membered carbo- or heterocyclic ring, aromatic or non-aromatic, optionally substituted with 1 to 2 C1-6 alkyl or 1 to 2 halogen and is directly attached to the rest of the molecule;
- except (+/−) 3,4-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-2H-pyrrol-5-amine.
11 more elements
A pharmaceutical composition comprising at least one compound of having formula I:
- wherein:
- n is 0 or 1;
- A is an aromatic or non-aromatic ring;
- X is N, N—R1, CH—R1, C—R1;
- R1 is H, C1-6 alkyl or halogen;
- R2 is N, N—R3, CH—R3, C—R3, O or S;
- R3 is H, halogen, or C1-6 alkyl;
- R4 is halogen, H, C1-6 alkyl or part of a ring as a S, O, N or as a C;
- R5 is a S, N or is a C and is always part of a ring;
- R6 is H, C1-6 alkyl, halogen or is part of a ring as a S, O, N or as a C;
- R4 and R5 can form a 5 or 6 membered carbo- or heterocyclic ring, aromatic or non-aromatic, optionally substituted with 1 to 2 C1-6 alkyl or with 1 to 2 halogen and is directly attached to the rest of the molecule;
- or
- R5 and R6 can form a 5 or 6 membered carbo- or heterocyclic ring, aromatic or non-aromatic, optionally substituted with 1 to 2 C1-6 alkyl or 1 to 2 halogen and is directly attached to the rest of the molecule;
- except (+/−) 3,4-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-2H-pyrrol-5-amine;
- and a pharmaceutically acceptable carrier.
12 more elements
Dependencies are inferred from the claim text.